Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338115 · ClinicalTrials.gov registry record
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 60
- Enrollment target
NCT02338115 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 60 participants.
The verdict
NCT02338115 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
Interventions
- DRUG Paclitaxel 80mg/m2 weekly x 12 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338115
The ClinicalTrials.gov registry entry for NCT02338115 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel 80mg/m2 weekly x 12 weeks is the first listed.
NCT02338115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02338115 about?
NCT02338115 is a clinical study titled "Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients". The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
What is the current status of trial NCT02338115?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2014-05. Estimated completion is 2016-12-20.
What interventions are being tested in trial NCT02338115?
The interventions under investigation include: Paclitaxel 80mg/m2 weekly x 12 weeks (DRUG).
Who is sponsoring clinical trial NCT02338115?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.